Illustration of a doctor reviewing Alzheimer’s blood test results influenced by kidney problems, for news article on study findings.
Image generated by AI

Kidney problems may skew Alzheimer’s blood test results, study suggests

Image generated by AI
Fact checked

A large study published in Neurology finds that impaired kidney function is linked to higher levels of Alzheimer’s biomarkers in the blood, without increasing overall dementia risk. However, among people who already have elevated biomarker levels, poor kidney health may hasten when dementia symptoms appear, underscoring the need to factor kidney function into interpretation of Alzheimer’s blood tests.

Published on December 3, 2025, in Neurology, the medical journal of the American Academy of Neurology, the study examined how kidney function relates to blood-based biomarkers of Alzheimer’s disease.

Led by Francesca Gasparini, MD, of Karolinska Institutet in Stockholm, Sweden, the research followed 2,279 community-dwelling adults with an average age of 72, none of whom had dementia at the start of the study. Participants underwent medical examinations, cognitive testing, and blood tests that assessed kidney function and measured several Alzheimer’s-related biomarkers, including tau and amyloid beta proteins, neurofilament light chain (NfL) proteins, and glial fibrillary acidic proteins (GFAP). 【0search1】【0search3】

Over an average follow-up period of about eight years, the researchers divided participants into two groups based on kidney function. Among 1,722 people with healthy kidney function, 221 developed dementia. In the group of 557 people with impaired kidney function, 141 developed dementia. 【0search1】【0search3】

The study found that reduced kidney function was associated with higher levels of most of the Alzheimer’s blood biomarkers examined. However, the authors emphasized that the results show an association rather than proof that poor kidney function directly causes these elevations. Kidneys normally help remove waste and toxins from the blood, which may help explain the link, according to the American Academy of Neurology news release and related coverage. 【0search1】【0search3】【0search8】

After adjusting for factors such as age, sex, and the APOEε4 genetic risk marker for Alzheimer’s disease, the researchers found that impaired kidney function was not linked to an overall increased risk of developing dementia when compared with preserved kidney function. 【0search1】【0search3】

A key finding involved a subgroup of participants with both impaired kidney function and elevated levels of neurofilament light chain. In this group, dementia risk was nearly twice as high as in people who had preserved kidney function but similarly elevated NfL levels, according to the American Academy of Neurology and ScienceDaily summaries. This pattern suggests that kidney health may influence the timing of dementia onset in people who already show signs of neurodegeneration, rather than substantially changing the overall likelihood of developing dementia. 【0search1】【0search3】【0search8】

"Our study found that when the kidneys are not functioning properly, there may be higher levels of Alzheimer’s biomarkers in the blood," Gasparini said. "While we did not find that having reduced kidney function increased the risk of developing dementia, we did find that impaired kidney function may accelerate the onset of dementia in people who have higher levels of biomarkers. This highlights the need for doctors to consider kidney function when interpreting results of Alzheimer’s biomarkers in the blood." 【0search1】【0search3】【0search8】

Gasparini underscored the clinical implications in remarks quoted by the American Academy of Neurology and partner outlets: "When looking at these biomarkers in older adults, keeping an eye on kidney health may be more important than one might think. Monitoring kidney health may help clinicians better interpret these biomarkers and identify who might be at risk for faster disease progression." 【0search1】【0search2】【0search3】

According to coverage by Medical Xpress and other outlets drawing on the Neurology paper, the study had several limitations. Alzheimer’s-related blood biomarkers were measured only once, so the researchers could not examine how changes in kidney function over time might affect biomarker levels. In addition, most participants were highly educated and lived in urban areas in Sweden, which may limit how broadly the findings apply to other populations. 【0search2】【0search3】【0search8】

Overall, the study suggests that in older adults, kidney health can meaningfully influence how Alzheimer’s blood tests should be interpreted, particularly for people with already elevated biomarker levels, even though reduced kidney function alone does not appear to raise overall dementia risk.

What people are saying

Initial reactions on X to the study are neutral and mostly consist of shares and summaries highlighting that impaired kidney function raises Alzheimer’s blood biomarkers without elevating overall dementia risk, but may accelerate symptom onset in those with elevated levels. Medical and science accounts emphasize the need for clinicians to account for kidney health in test interpretations.

Related Articles

Realistic split-image illustration showing obesity-linked faster rise in Alzheimer’s blood biomarkers versus normal weight, highlighting blood tests detecting changes earlier than brain scans.
Image generated by AI

Obesity linked to faster rise in Alzheimer’s blood biomarkers, study finds

Reported by AI Image generated by AI Fact checked

New research finds that blood biomarkers associated with Alzheimer’s disease increase significantly faster in people with obesity than in those without. Drawing on five years of data from 407 volunteers, the study suggests that blood tests can detect obesity‑related changes earlier than brain scans, underscoring obesity as a major modifiable risk factor for Alzheimer’s.

New research reveals that blood from younger mice can protect against Alzheimer's-like brain damage, while older blood accelerates it. Scientists conducted experiments infusing mouse blood over 30 weeks to observe effects on memory and protein buildup. The findings highlight blood's role in brain health and potential new treatments.

Reported by AI

European scientists have developed a preliminary method to identify Alzheimer's using a drop of dried blood from a finger, achieving 86% accuracy in detecting amyloid pathology. The study, validated in 337 patients from several countries, is published in Nature Medicine and aims to simplify early diagnosis of this disease affecting over 50 million people worldwide.

Researchers in Sweden and Norway have identified biological markers in the blood that signal the earliest stages of Parkinson's disease, potentially allowing detection up to 20 years before motor symptoms appear. The study, published in npj Parkinson's Disease, highlights a brief window where these markers are detectable, offering hope for earlier diagnosis and treatment. Blood tests based on this discovery could enter healthcare testing within five years.

Reported by AI

A recently recognized form of dementia, known as LATE, is reshaping understanding of cognitive decline in the elderly, with rising diagnoses and guidelines for doctors published this year. It is estimated to affect about one-third of people aged 85 or older and 10% of those aged 65 or older, often mistaken for Alzheimer's. Experts emphasize the need for a broader range of treatments for this condition.

New research indicates that poor sleep quality can make the brain age faster than the body, potentially increasing risks for conditions like dementia. Scientists suggest chronic inflammation from inadequate sleep plays a key role in this process. This finding clarifies a long-standing uncertainty about whether bad sleep causes cognitive decline or merely signals it.

Reported by AI Fact checked

Researchers at Washington University School of Medicine in St. Louis report that amyloid pathology in mouse models of Alzheimer’s disease disrupts circadian rhythms in microglia and astrocytes, altering the timing of hundreds of genes. Published October 23, 2025, in Nature Neuroscience, the study suggests that stabilizing these cell-specific rhythms could be explored as a treatment strategy.

 

 

 

This website uses cookies

We use cookies for analytics to improve our site. Read our privacy policy for more information.
Decline